Drug Trial Radar · NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
444
Planned (sponsor's estimate)
Start
Aug 28, 2024
Primary completion
Oct 28, 2027
Study completion Jun 27, 2029
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jun 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer that has spread nearby or to other parts of the body or is unlikely to be controlled with current treatments. HER2 is a protein that helps cells to grow and divide. Sometimes, cancer cells have a damaged HER2 gene. This is called a mutation. This mutation can lead to an abnormal HER2 protein which may cause cancer cells to grow and divide too quickly. The study treatment, sevabertinib, is designed to block the mutated HER2 protein and may help slow or stop the cancer from growing. The main purpose of this study is to find out how well sevabertinib works and how safe it is, compared with standard treatment in participants with advanced NSCLC with a HER2 mutation. The study participants will receive one of the study treatments: * Sevabertinib as a tablet taken by mouth twice a day * Standard approved treatment for this condition given by infusion into a vein every 21 days Participants will continue their assigned treatment for as long as they benefit from it and do not experience severe side effects, or until they or their doctor decide to stop treatment. When a participant assigned to the standard treatment has their cancer gets worse, they may have the opportunity to switch to receive sevabertinib. This switch is called a crossover. Participants who switch to sevabertinib will continue this treatment until their disease gets worse again, they have side effects that are too severe, or they or their doctor decide to stop treatment. During the study, the research team will: * do scans such as CT, PET, MRI, or X-rays to check the cancer * Check the overall health of the participants by performing tests such as blood and urine tests and checking heart health using an electrocardiogram and echocardiogram. * do pregnancy tests when needed * ask how the participants are feeling and whether they have had any adverse events or other health problems An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Conditions
- Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions
SevabertinibDrug
Tablet, oral
PembrolizumabDrug
Intravenous (IV) infusion
CisplatinDrug
IV infusion
CarboplatinDrug
IV infusion
PemetrexedDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) per RECIST 1.1 as assessed by BICRTime frame: Up to approximately 2 years
Locations
279 sites in 36 countries. Site status is shown where the registry gives one.
Patty & George Hoag Cancer Center
Newport Beach, California · Withdrawn
UC San Diego Health - Moores Cancer Center
San Diego, California · Withdrawn
UCSF Bakar Precision Cancer Medicine Building - Thoracic Surgery and Oncology
San Francisco, California · Recruiting
UCLA Health Santa Monica Cancer Care
Santa Monica, California · Recruiting
The Oncology Institute of Hope and Innovation - Fort Lauderdale 17th Street
Fort Lauderdale, Florida · Recruiting
Memorial Cancer Institute at Miramar
Miramar, Florida · Withdrawn
AdventHealth Cancer Institute Orlando
Orlando, Florida · Not yet recruiting
Moffitt Cancer Center - Magnolia Campus
Tampa, Florida · Withdrawn
Piedmont Healthcare - Atlanta
Atlanta, Georgia · Recruiting
John B. Amos Cancer Center
Columbus, Georgia · Recruiting
University of Illinois Hospital - Outpatient Cancer Care Center
Chicago, Illinois · Recruiting
The University of Chicago Medical Center - Hyde Park - Hematology & Oncology
Chicago, Illinois · Withdrawn
UM Greenebaum Comprehensive Cancer Center
Baltimore, Maryland · Not yet recruiting
UMass Memorial Medical Center - University Campus - Hematology/Oncology
Worcester, Massachusetts · Withdrawn
Profound Research -OMG - TriAtria Cancer Center
Farmington Hills, Michigan · Withdrawn
Profound Research - OMG - Royal Oak Cancer Center
Royal Oak, Michigan · Withdrawn
M Health Fairview Masonic Cancer Clinic - Clinics and Surgery Center
Minneapolis, Minnesota · Withdrawn
R.J. Zuckerberg Cancer Center
New Hyde Park, New York · Withdrawn
UC Medical Center - Oncology
Cincinnati, Ohio · Recruiting
Taylor Cancer Research Center
Maumee, Ohio · Recruiting
Providence Cancer Institute - Franz Clinic
Portland, Oregon · Withdrawn
Providence Oncology and Hematology Care Clinic Westside
Portland, Oregon · Withdrawn
Allegheny General Hospital
Pittsburgh, Pennsylvania · Recruiting
University Hospital Simmons Cancer Center Lung/Head Neck Clinic
Dallas, Texas · Withdrawn
The University of Texas MD Anderson Cancer Center - Texas Medical Center
Houston, Texas · Recruiting
Fundación Cenit para la Investigación en Neurociencias
Buenos Aires, Argentina · Withdrawn
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina · Withdrawn
Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)
Buenos Aires, Argentina · Withdrawn
Centro Médico Privado CEMAIC
Córdoba, Argentina · Withdrawn
Instituto Argentino de Diagnostico y Tratamiento (IADT)
TBC, Buenos Aires, Argentina · Withdrawn
Centro de Investigaciones Clínicas, Clínica Viedma
Viedma, Río Negro Province, Argentina · Withdrawn
NSW Health - Blacktown Hospital
Blacktown, New South Wales, Australia · Active not recruiting
Concord Repatriation General Hospital - Medical Oncology Clinical Trials Unit
Concord, New South Wales, Australia · Completed
Calvary Mater Hospital Newcastle - Oncology
Waratah, New South Wales, Australia · Active not recruiting
University of the Sunshine Coast
Buderim, Queensland, Australia · Withdrawn
Toowoomba Hospital Oncology Clinical Trials
Toowoomba, Queensland, Australia · Withdrawn
Austin Hospital - Olivia Newton John Cancer Research Institute
Heidelberg, Victoria, Australia · Active not recruiting
Klinik Floridsdorf, Pneumo-onkologische Ambulanz und Tagesklinik
Vienna, Austria · Active not recruiting
Uniklinikum Salzburg, Universitätsklinik für Innere Medizin III
Vienna, State of Salzburg, Austria · Withdrawn
Uniklinikum Salzburg, Universitätsklinik für Pneumologie/ Lungenheilkunde
Vienna, State of Salzburg, Austria · Withdrawn
Showing 40 of 279 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.